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Heart rate variability after BRL37344, a beta-3 
agonist, in experimental bladder outlet obstruction
Analiza zmienności rytmu serca (HRV) po podaniu 
BRL37344, agonisty receptora beta-3 adrenergicznego, 
w doświadczalnym modelu blokady podpęcherzowej
Łukasz Dobrek , , , , , , , Agnieszka Baranowska , Piotr J. Thor , 
Department of Pathophysiology, Jagiellonian University Medical College
Summary
Bladder overactivity symptoms accompany benign prostatic hyperplasia (BPH) syndrome. The 
autonomic nervous system (ANS) disturbances may be involved in bladder dysfunction. An 
ameliorating effect on bladder overactivity is being assigned to the currently investigated β-3 
adrenoreceptor agonists. However, little is known about the influence of β-3 agonists on ANS 
activity. The aim of our study was to estimate ANS activity using heart rate variability (HRV) 
in experimental model of bladder outlet obstruction (BOO), reflecting human BPH.
30 female rats, divided into control, non-treated BOO (LLBOO), and β-3 agonist (BRL37344) BOO 
treated (LLBOO+β3 agonist) were studied. BOO was evoked by 5-week long partial proximal 
urethra ligation. Next, 20-minute resting HRV recordings were performed in each of the studied 
groups following i.p. administration of the vehicle (LLBOO) or BRL37344 (LLBOO+β3 agonist).
LLBOO rats were characterized by diminished NN range, SDNN, and rMSSD in time-domain 
analysis. Similarly, TP and non-normalized spectral HRV parameters were also decreased. 
Contrary to these findings, normalized spectral parameters were lower (nLF) and higher 
(nHF). The animals treated with BRL37344 demonstrated no significant differences in time-
-domain HRV parameters. In spectral analysis, a decrease in LF and HF, together with a fall 
in TP, was found. Moreover, both nLF and nHF reached almost the same values in control and 
β-3 agonist treated rats.
Our data indicates that BRL37344 is an agent abolishing the autonomic imbalance in experi-
mental BOO, which may contribute to relieving the symptoms of bladder overactivity in β-3 
agonists treated participants.
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IntroductIon
Overactive bladder (OAB) is a clinical condition currently 
classified by the International Continence Society (ICS) as 
a symptom syndrome suggestive of lower urinary tract 
dysfunction. It is defined as denoting urgency with (“wet” 
OAB) or without (“dry” OAB) urge incontinence, usually 
with increased daytime frequency and nocturia, and in 
the absence of local or metabolic factors to explain these 
symptoms [38,40]. Notably, the current description of OAB 
is not only based on the urodynamic findings. Though the 
notion of “overactive detrusor” has appeared in previous 
ICS publications, and sometimes was used interchange-
ably with OAB, it was never the intention of the ICS com-
mittee, however, to apply OAB definition only to the 
urodynamic status. Originally, overactive detrusor was an 
urodynamic-based term, reflecting abnormal, involun-
tary detrusor contractions (which may be spontaneous 
or provoked) during filling cystometry. Overactive detru-
sor may be considered in terms of detrusor hyperreflexia 
(caused by neurologic disturbances) or unstable detrusor 
(caused by non-neurogenic factors). The latter was often 
described as “idiopathic detrusor instability” [38]. Thus, 
the multitude of employed qualifications motivated ICS to 
standardize the overactive bladder terminology and pub-
lish diagnostic guidelines. The currently endorsed defini-
tion of OAB is based on patient’s subjective perception of 
lower urinary tract dysfunction and assigns a lesser sig-
nificance to cystometry [38]. Urgency, a sensation asso-
ciated with bladder filling, is a key OAB symptom. It is 
considered to be difficult to describe to those who have 
not experienced it; however, it may be described as a sud-
den, and difficult to defer, compelling desire to pass urine. 
This complaint leads to the remaining urinary symptoms 
– diminished intervoiding intervals (increased urina-
tion frequency; pollaksiuria), nocturia, incontinence and 
reduced urinary volume [8]. Increased daytime frequency 
is the complaint of voiding too often during the day. Noc-
turia is the necessity to get up one or more times dur-
ing the night to void. Urge incontinence (in the so called 
“wet” OAB) is characterized by a strong desire to void 
together with an involuntary urine leakage [38].
There are difficulties in evoking OAB for the purposes of 
medical experiments because it is hard to unequivocally 
ascertain whether an animal is experiencing urgency. 
Therefore, as it is not technically possible to create 
an ideal OAB model, surrogate models are employed, 
including bladder outlet obstruction (BOO). This model 
is characterized by bladder overactivity initially condi-
tioned by anatomical abnormalities of the lower urinary 
tract and not by primary neurogenic and/or myogenic 
disturbances of the bladder [32].
OAB is a relatively common medical condition, affect-
ing 12-18% of the population, and known to increase 
with age in both genders; although, women seem to be 
affected to a larger extent [12]. In USA, it is estimated 
that one in 11 adults suffers from OAB, and a total of 17 
million adults are affected [6]. In Europe, the Milsom 
et al. [30] study revealed that 16.6% of all respondents 
(15.6% of men and 17.4% of women) have reported symp-
toms suggestive of OAB. However, it must be emphasized 
that OAB prevalence depends on the design of the epi-
demiological study; mostly, on the OAB incision/exclu-
sion criteria. The overall consensus is that urgency and 
frequency constitute the main complaints, while urge 
incontinence is displayed by only a third of the patients. 
However, all OAB symptoms are taxing for the patients 
and have a negative impact on the quality of life [15].
The pathophysiology of overactive bladder is complex, 
resulting from both neurogenic and myogenic distur-
bances. According to myogenic OAB theory, bladder 
overactivity develops as a result of abnormal coupling 
and myoelectrical activity of the smooth muscles [3]. 
However, it is the theory of disturbed nervous system 
control that is strongly favoured with regards to the 
pathogenesis of AOB. Probably, a combination of dis-
turbances in both the central and peripheral neural 
mechanisms is responsible for urgency and other OAB 
symptoms. These mechanisms involve both central and 
peripheral sensory (increased bladder receptor excit-
ability and/or afferent bladder output, abnormal cen-
tral processing of afferent discharge) as well as motor 
(increased smooth muscle contractility induced by neu-
ral and non-neural stimuli, involuntary immoderate 
parasympathetic nerve supplying reflexes) aspects [3,8]. 
Moreover, the current pathophysiology of OAB empha-
sizes the role of the urothelium, a multifunctional tissue 
that not only acts as a barrier between the bladder con-
tents and the underlying tissues, but is also considered 
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eral types of potassium channels have been investigated 
in bladder tissues, including voltage-gated, small conduc-
tance, ATP-sensitive, and large conductance, with the lat-
ter demonstrated to possess the predominant role [14]. 
In general, calcium channels classified into dihydropyr-
idine-sensitive L-type voltage-gated ones are responsible 
for depolarisation, intracellular calcium influx and fol-
lowing urinary bladder smooth muscle contractions. The 
repolarisation period is regulated mainly by BK potassium 
channels mentioned above. There are evidences that the 
activation of β-3 adrenoreceptors by BRL37344 and other 
agonists involves increased Ca-dependent smooth mus-
cles hyperpolarisation and their relaxation [1,19]. More-
over, apart from direct action on bladder smooth muscle, 
the relaxing effect of β-3 adrenoreceptor agonists may 
also result from the release of urothelium-derived nitric 
oxide (NO). The indirect confirmation on the role of NO in 
bladder filling are the results confirming that intravesical 
administration of NO donors diminishes detrusor hyper-
activity, whereas oxyhemoglobin (NO scavenger) stimu-
lates bladder activity [14].
It is also worth remembering that relaxing action of 
NO, secondary to β-3 bladder adrenoreceptors activa-
tion, may not be mediated by a direct action on smooth 
muscle cells, because they lack soluble guanylate cyclase 
– an important component in NO-mediated relaxation. 
Instead, NO may modulate bladder reflexes by altering 
activity of the afferents. This mechanism of β-3 adreno-
receptors-evoked bladder relaxation provides further 
insights into the role of urothelial cells in the sensory 
functions of the bladder [4,5].
In conclusion, there are many premises supporting the 
concept that selective agonistic impact on β-3 adreno-
receptors may be an effective pharmacological option 
to treat bladder over-contractility. The role of β-3 adr-
enoreceptors and their agonists in management of blad-
der overactivity is currently under intense investigation. 
There are several reports demonstrating the beneficial 
role of β-3 agonists in animal OAB models (experimen-
tal conditions with the presence of bladder overactiv-
ity symptoms, which are thought to mirror human OAB; 
further explained in the text above). Woods et al. [41] 
found that CL316243, a selective β-3 adrenoreceptors 
stimulant, inhibits the smooth muscle cells contractil-
ity in depolarized, isolated rat detrusor strips. Hicks et 
al. [18] confirmed the results of previously mentioned 
investigators, reporting that GW427353 (solabegron) 
also evokes bladder relaxation and facilitates bladder 
storage mechanisms in dog isolated bladder strips. Fur-
ther experimental evidence was supplied by Kaidoh et 
al. [20] study, who demonstrated that the administra-
tion of CL316243 suppresses the detrusor hyperreflexia 
in infarcted rat brain. Another study by Kullmann et al. 
[24] revealed that in rat ovariectomy OAB model β-3 adr-
enoreceptors agonist, BRL37344, decreases voiding fre-
quency by 40 to 70%; thus, suggesting the potential role 
of β-3 adrenomimetic ligands in the treatment of blad-
der hyperactivity in this setting. The encouraging results 
to be a sensory organ, transducing physical and chemi-
cal stimuli to the attendant afferent nerves and smooth 
muscles of the bladder [5].
Since the pathogenesis of OAB has not been fully eluci-
dated so far, treatment is aimed at relieving the symp-
toms rather than curing. There are several treatment 
options, including conservative treatment, oral phar-
macological agents, intravesical therapy, or surgery 
[17]. The potential sites for pharmacological interven-
tion consist of the smooth muscles of the bladder, effer-
ent/afferent nerves, and the central nervous system. 
The current, typical pharmacological management of 
OAB involves antimuscarinics (anticholinergic medica-
tions) as a result of their confirmed inhibitory role with 
regards to the muscarinic receptors. Human bladder 
mostly contains M2 and M3 receptors; it is postulated 
that these receptors evoke contraction of the smooth 
muscles and are involved in sensory (afferent) activa-
tion. Six antimuscarinics are approved for OAB treat-
ment: oxybutynin, tolterodine, trospium, propiverine, 
solifenacin, and darifenacin. All have received excellent 
rating (level 1 – data from randomized controlled stud-
ies, grade A – highly recommended). However, antimus-
carinics can produce unwanted side effects (dry mouth, 
constipation, dizziness, and headache) [17,39]. Thus, 
OAB management continues to evolve with the develop-
ment of a number of new concepts.
β-3 adrenoreceptor agonists are among the new concepts 
considered during the development of new AOB manage-
ment options. It has been discovered that the stimulation 
of β-3 receptor results in an increase in the heart rate, 
lipolysis with higher energy expenditure, and improved 
glycemic control [33]. Thus, β-3 agonists have been con-
sidered as therapeutic agents for experimental obesity, 
type 2 diabetes, and heart failure treatment; however, the 
results of the clinical trials have not been encouraging 
[33]. Rat β-3 adrenoreceptors were found to be expressed 
in brown and white adipocytes, liver, skeletal muscle, 
ileum, colon, and brain. The presence of β-3 adrenore-
ceptors in humans has been confirmed in adipose, small 
intestine, colon, stomach, heart, and brain [16]. Moreover, 
β-3 adrenoreceptors have been identified in both rat and 
human bladders and stimulation of β-3 adrenoreceptor is 
thought to be a valuable approach for the treatment of 
frequent urination and urinary incontinence, because 
there is evidence indicating that detrusor relaxation is 
mediated through activation of this receptor [16,33]. The 
signalling pathway of β-3 adrenoreceptors includes the 
activation of adenylyl cyclase with the subsequent cAMP 
formation. Nevertheless, it seems that this mechanism 
does not have a crucial contribution to adrenomimetic-
mediated bladder relaxation. Bigger importance for β-3 
agonists-mediated bladder relaxation is attributed to the 
activation of potassium channels, leading to the efflux of 
potassium, hyperpolarisation, and reduced tone of the 
smooth muscle cells [14,19]. Increased cAMP activates 
protein kinase A and finally results in large-conductance 
calcium activated potassium BK channels excitation. Sev-
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Animals,  studied groups and general study 
plan:  The animals (female 8-week-old Wistar rats) 
were obtained from the central laboratory. Upon 
arrival at the animal house at the Pathophysiology 
Department, the rats were allowed an acclimatisation 
period of one week in groups of five per cage. The ani-
mals were housed at room temperature, with 12-12 
hours day-night cycle, with standard food (Labofeed 
Kcynia) and water ad libitum.
We performed our study using 30 rats. After the accli-
matisation period, 20 animals (starting mean body 
weight 181.67 ± 7.82 g) underwent surgically induced 
proximal bladder outlet obstruction (BOO; see below), 
while 10 sham-operated rats were enrolled into the con-
trol group. The BOO rats were then maintained for five 
weeks to allow for bladder overactivity due to devel-
oping bladder outlet obstruction (long-lasting blad-
der outlet obstruction; LLBOO). After this time, the 
animals were randomised into the non-treated group 
(LLBOO) and the β-3 agonist (BRL37344) treated group 
(LLBOO+BRL37344). The studied compound, BRL 37344, 
was obtained from Sigma Aldrich. We planned to per-
form HRV recordings with statistical control/LLBOO/
LLBOO+BRL37344 differences analysis and bladder mac-
roscopic and histological assessment in all studied ani-
mals. The final body weight at the end of the experiment 
was 221.14 ± 11.35 g in LLBOO rats and 259.51 ± 8.22 g in 
control animals.
L o n g - l a s t i n g  b l a d d e r  o u t l e t  o b s t r u c t i o n 
model:  20 animals enrolled into the BOO group under-
went surgery to induce partial urine outflow obstruc-
tion, leading to bladder overactivity. The technique 
used to obtain bladder outlet obstruction, both in grow-
ing and mature animals, has already been described in 
the 1980s by a number of investigators, for example, 
Sibley (1985) [36], and it is still used with small modi-
fications by numerous researchers (e.g. Das et al.; 2002 
[11], Kamiyama et al.; 2007 [21]). This experimental 
model is considered to produce similar bladder over-
activity as that observed in OAB. Moreover, BOO ani-
mal model faithfully mimics bladder overactivity due to 
benign prostatic hyperplasia (BPH) in humans. It shows 
many of the structural and physiological bladder wall 
changes observed in human BOO, including muscle cells 
hypertrophy, altered responsiveness to various stimuli, 
increased myogenic activity, and enlarged sensory neu-
rons with non-micturition contractions. Thus, partial 
long-lasting BOO appears to be a good model to recapit-
ulate bladder overactivity symptoms; especially, those of 
bladder overactivity secondary to BPH [32].
The rats were briefly anesthetised with sodium pen-
tobarbital (Morbital, Biowet, Puławy; 35 mg/kg body 
weight) intraperitoneally (i.p.). Under general anaes-
thesia, a 1 mm diameter stainless urinary catheter was 
placed into the urethra. After performing a lower mid-
line laparotomy, the bladder and proximal urethra were 
exposed and a 4/0 silk ligature was tied around the 
of experimental studies, not only with regards to OAB, 
introduced β-3 agonists to the clinical trials, enabling 
the assessment of their effectiveness and safety. At the 
present, several ligands have been investigated, includ-
ing solabegron (GW427353; GlaxoSmithKline; completed 
phase II for OAB and irritable bowel treatment), amibe-
gron (SR58611; Sanofi-Aventis; completed phase III for 
anxiety and depressive disorders treatment), mirabe-
gron (YT178; Astellas), and ritobegron (KUC7483; Kis-
sei), both studied for OAB treatment, as well as LY377604 
(Elly Lilly) and L-796568 (Merck), which were tested as 
anti-obesity and type 2 diabetes compounds [33]. The 
preliminary results confirm the experimental findings, 
indicating that the studied β-3 agonists will be regis-
tered as new OAB medication in the close future. On 
the other hand, clinical trials also revealed a number 
of side effects of these agents; probably, limiting their 
wide usage in OAB treatment. For example, solabegron 
was found to produce visceral hyperalgesia by releas-
ing somatostatin from adipocytes, while amibegron 
was demonstrated to produce abnormalities in hepatic 
functioning [33]. Moreover, BRL37344 was also noted to 
increase the levels of circulating transaminases, accom-
panied by dynamic changes in glucose metabolism [22].
Apart from the indisputable evidence confirming the 
effectiveness of β-3 agonists in OAB management, a 
number of pharmacological aspects of β-3 agonist’s 
action need to be defined. For example, the effect of β-3 
adrenoreceptor stimulation on the autonomic nervous 
system activity during OAB is still not fully explained. 
Therefore, the present study was designed to investigate 
the probable β-3 adrenoreceptor-mediated changes in 
autonomic nervous system (ANS) activity, following the 
administration of one of the β-3 agonists, BRL37344, in 
a rat OAB model evoked by long-lasting bladder outlet 
obstruction. ANS functioning can be assessed non-inva-
sively using heart rate variability (HRV) method, based 
on the ECG signal. The fundamental assumption in HRV 
analysis is that the rhythmical sinus heart rate is influ-
enced by both sympathetic and parasympathetic modu-
lation, which is reflected by the main HRV parameter 
and referred to as the mean time between successive 
normal-normal intervals (mean NN), as well as numer-
ous mean NN-derived secondary statistical parameters 
(time-domain HRV analysis). HRV is also analysed after 
transforming the primary ECG recording into the so 
called HRV spectrum (with its total power; TP), which 
can be divided according to the frequency range into 
some non-normalized (at very low frequencies – VLF, 
low – LF, and high – HF) components and normalized 
(nLF, nHF) parameters, reflecting global (TP), pure sym-
pathetic (nLF), pure parasympathetic (nHF, HF), and 
both ANS branches (LF) tone [27,34].
MaterIals and Methods
Ethics: The study protocol was approved by the First 
Local Ethic Committee in Cracow (agreement decision 
126/2010).
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nLF and nHF in [n.u.]) parameters were calculated. The 
spectrum bands for respective components were set as: 
0.18<VLF<0.28<LF<0.78<HF<3. Commonly accepted inter-
pretation criteria were employed, according to HRV 
guidelines [2,27,34]. Results were presented as mean val-
ues ± SD.
We accepted such frequency bands for the individ-
ual HRV components as it has been mentioned above 
according to previously published Cerrutti et al [7] and 
Aubert et al. [2] studies. However, depending on the 
studied experimental model and species of the studied 
animals, various frequency ranges determining HRV 
spectral components powers are accepted. Some of them 
are given in Rowan III et al review [34]. Thus, one should 
always remember about these methodological details 
when compared one’s results to those ones obtained in 
another studies.
Stat is t ica l  HRV parameters  analys is :  The 
statistical assessment of the results was performed in 
paired studied groups (control vs. LLBOO; control vs. 
LLBOO+BRL37344, and LLBOO vs. LLBOO+BRL37344) 
using parametric Student’s t-test with α=0.05. The H0 
hypothesis of equality of analysed parameter variations 
in two studied populations was verified versus an alter-
native H1 hypothesis, which assumed their inequality 
(and thus the existence of statistically significant differ-
ences).
Urinary bladder assessment: In all studied rats, 
the bladders were collected once the HRV recordings 
had been taken and a lethal sodium pentobarbital dose 
(100 mg/kg body weight) was administered, in order to 
compare the changes in bladder wet weight (BWW) and 
its percentage related to final body weight in control and 
LLBOO animals. Bladders were cut off with the proximal 
ligated (LLBOO rats) or normal (controls) urethra. They 
were gently drained of their content using gauze and 
immediately weighted. According to literature, cystitis 
may be evaluated not only by determining the changes in 
macroscopic and microscopic analysis, but also via blad-
der wet weight. Thus, BWW is regarded as an indirect 
marker of cystitis and bladder dysfunction [31,35,42].
results
Bladder wet weight in studied groups:  BWW 
values did not differ in both control and obstructed 
animals. Mean bladder wet weight was 0.137 ± 0.064 g 
(range 0.04 to 0.22 g) in sham operated controls vs. 0.147 
± 0.058 g (range 0.11 to 0.34 g) in LLBOO rats.
Nonetheless, we revealed that although there was no 
difference in BWW in both control and LLBOO rats, the 
percentage of bladder wet weight in relation to final 
body weight differed in these populations (0.046 ± 0.021 
g vs. 0.066 ± 0.024 g, respectively; p=0.04). Thus, BWW 
increase in LLBOO animals suggests rebuilding of the 
bladder wall and its dysfunction in this group.
proximal urethra and the inserted rod. Following this, 
the catheter was removed leaving the urethra partially 
occluded. The laparotomy incision was then closed, two 
antibiotics (neomycinum – Neomycin spray, oxytetracy-
clinum – Oxycort spray) were administrated through the 
surgery wound and the animals were allowed to recover. 
One of the operated animals died during the surgery and 
three others in the early postoperative period. Thus, in 
the end, we studied 16 LLBOO participants.
LLBOO group:  8 rats were randomised into the con-
trol group. Prior to HRV recordings, these animals were 
given i.p. 0.9% saline in the appropriate volume, similar 
to β-3 agonist treated animals.
LLBOO+BRL37344 group (β-3 agonist treated 
group):  8 rats were randomised into this group. The 
rats were administrated single i.p. dose of β-3 ago-
nist, labelled in Sigma Aldrich as BRL37344 sodium salt 
hydrate ((±)-(R*,R*)-[4-[2-[[2-(3-Chlorophenyl)-2-hy-
droxyethyl]amino]propyl]phenoxy]acetic acid sodium 
hydrate).
According to previously published Kullman et al. [24] 
study, we used BRL37344 dose of 5 mg/kg body weight, 
taking into consideration their findings confirming that 
this dose had a consistent and significant effect on void-
ing frequency. BRL37344 was dissolved in water and 
administrated prior to HRV recording.
Control  group:  10 animals (starting body weight 
180.34 ± 6.82 g) were sham-operated without proximal 
urethra ligation. All animals from this group survived 
the operating intervention and were kept for the same 
time and in the same conditions as those from LLBOO 
group. HRV recordings in control rats were taken with-
out the vehicle or β-3 agonist.
HRV studies: On the fifth week after BOO induction, 
HRV recording was taken in all studied animals. Firstly, 
animals were treated with vehicle (LLBOO group) or β-3 
agonist (LLBOO+BRL37344). Control rats did not receive 
these agents. In LLBOO, HRV recordings were performed 
2-4 hours after drug or vehicle treatment in compliance 
to Kullman et al. [24] findings, demonstrating that the 
effect of BRL37344 lasted for 4 to 6 hours.
In each studied animal, ECG recordings were taken 
under urethane anaesthesia (1200 mg/kg body weight; 
Sigma-Aldrich) during the 20-minute rest periods. This 
anaesthetic agent was chosen after taking into consid-
eration literature reports suggesting proportional (up 
to the applied dose) impact on tonic activity of both 
the sympathetic and parasympathetic ANS elements 
and a relatively small influence on cardiac reflexes 
[25,26]. HRV analysis was performed after terminating 
ECG registration and eliminating extrasinusal extop-
ics. Standard time (mean NN, max NN, min NN, SDNN 
– all in [ms]; rMSSD, mean HR [bpm]), spectral (fre-
quency; TP, VLF, LF, HF – all in [ms*ms]; and normalised 
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13.01±7.35 vs. 1.33 ± 0.39; respectively). We found no essen-
tial differences comparing time-domain HRV parameters 
in control and BRL-treated rats, except rMSSD value, which 
was significantly higher in the control group (13.01 ± 7.35 
vs. 6.02 ± 3.29).
The comparison between LLBOO and LLBOO 
treated rats :  Mean NN interval and its maximal 
value, together with average heart rate did not differ 
significantly in both groups. Minimal NN reached higher 
values in control rats (153.58 ± 11.72) as compared to β-3 
treated animals (140.07 ± 1.24; p=0.03). The latter group 
also displayed higher values of both SDNN (7.30 ± 1.55 vs. 
4.13 ± 1.68 in the controls; p=0.01) and rMSSD (6.02 ± 3.29 
vs. 1.33 ± 0.39 in controls; p=0.02).
When analysing the general trend observed in time-
domain HRV parameters in BRL37344 treated group, it 
should be emphasised that some of those mentioned 
above (mean NN, max NN, average HR) were almost 
identical when compared to the controls, while oth-
ers were increased. The summary of time-domain HRV 
parameters is given in table 2.
HRV spectral-domain parameters:
The comparison between our control and lit-
erature-based control  rats:  The spectral com-
ponents values demonstrated in our study were lower 
comparing to those ones revealed by Aubert et al [2] (our 
results: TP-36.09 [ms2]; LF-5.40 [ms2]; HF-11.47 [ms2] vs. 
78.98; 18.42 and 15.66; respectively). The differences may 
be due to both various time of HRV recordings (we col-
lected ECG signal for 20 minutes while Aubert et al [2] 
did it for 30-minutes) and the studied animals status (we 
performed HRV recordings in rats under urethane anaes-
thesia while they studied unrestrained animals). These 
methodological aspects might contribute to HRV spec-
trum power augmentation in Aubert et al. [2] study. 
The comparison between control  and both 
treated and non-treated LLBOO rats :  Most 
values of HRV spectral parameters were considerably dif-
The description of the LLBOO and control rats is given 
in table 1.
HRV time-domain parameters
The comparison between our control and lit-
erature-based control rats:  The values of the time-
domain parameters obtained in our study are partly similar 
to those ones found by Aubert et al [2]. We revealed mean 
NN as 163.41 [ms] and min NN as 139.28 [ms] and these 
results were in concordance with their study (mean NN – 
174.20 [ms] and min NN – 131.0 [ms[). On the other hand, 
however, we found a lower max NN result (188.76 [ms] vs. 
213.0 [ms]) and higher rMSSD value (13.01 [ms] vs. 5.2 [ms]) 
comparing to Aubert’s study [2].
The comparison between control  and both 
treated and non-treated LLBOO rats :  Mean 
NN did not differ in comparison between the control and 
LLBOO rats, both treated and non-treated. Analysing con-
trol and non-treated LLBOO populations, we revealed sta-
tistically higher range, SDNN, and rMSSD values in control 
rats (49.47 ± 6.47 vs. 31.06 ± 9.41; 8.70±2.73 vs. 4.13 ± 1.68; 









180.34 ± 6.82 181.67 ± 7.82 NS
Final body weight
[g]
259.51 ± 8.22 221.14 ± 11.35 NS
bladder wet weight
[g]
0.137 ± 0.064 0.147 ± 0.058 NS
bladder wet weight 
percentage related to 
final body weight
[%]
0.046 ± 0.021 0.066 ± 0.024 p = 0.04
Table 2. Time-domain HRV analysis results




mean NN [ms] 163.41±10.27 171.94 ± 14.84 170.77 ± 6.26 NS NS NS
max NN [ms] 188.76±6.28 184.62 ± 9.53 187.02 ± 2.12 NS NS NS
min NN [ms] 139.28±6.36 153.58 ± 11.72 140.07 ± 1.24 0.02 NS 0.03
range [ms] 49.47±6.47 31.06 ± 9.41 46.94 ± 2.16 0.006 NS 0.01
average HR [bpm] 368.32±22.55 351.32 ± 34.14 351.42 ± 12.97 NS NS NS
SDNN 8.70±2.73 4.13 ± 1.68 7.30 ± 1.55 0.008 NS 0.01
rMSSD 13.01±7.35 1.33 ± 0.39 6.02 ± 3.29 0.01 0.05 0.02
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relating to almost all calculated parameters, both non-
normalized (TP, VLF) and normalized (nLF, nHF). Both 
TP (12.21 ± 11.88) and VLF (9.64 ± 9.80) were consider-
ably higher in BRL37344 treated animals, as compared 
to the controls (2.68 ± 1.29 and 2.06 ± 1.02; respectively; 
p=0.05). Moreover, a considerable increase in LF/HF 
ratio was revealed in this group (0.63 ± 0.44 vs. 0.26 ± 
0.16). We also noted an increase in LF and HF powers in 
β-3 treated animals, as compared to the controls, but it 
was statistically insignificant. Conversely, normalised 
nLF value was significantly higher (34.77 ± 17.52) and 
nHF lower (65.23 ± 17.52) in β-3 agonist treated group 
when compared with the control (19.67 ± 9.59 and 80.33 
± 9.59, respectively; p=0.05).
The HRV spectral analysis detailed results mentioned 
above are given in table 2 and have been also presented 
as a visual summary in the figures 1 and 2.
Moreover, we calculated the percentage of individual 
power spectral components in total HRV power in both 
ferent in control and LLBOO, non-treated animals. We 
revealed a deep fall in all non-normalized spectral param-
eters, together with HRV total power in LLBOO rats. More-
over, the normalized spectral components were also 
different in these two populations, with nLF/nHF quo-
tient of about 1/2 in the control group (36.61 ± 16.04/63.39 
± 16.04; respectively) and 1/4 in LLBOO rats (19.67 ± 
9.59/80.33 ± 9.59). When the controls were compared to 
LLBOO+BRL37344 groups, a similar tendency of statistically 
significant, diminished non-normalized spectral param-
eters was observed (except VLF), although somewhat 
higher values were reached in LLBOO-β-3 agonist treated 
animals then in the non-treated rats. In the contrast to the 
findings mentioned above, no differences related to nor-
malized spectral parameters were displayed in the control 
– LLBOO+BRL37344 populations.
The comparison between LLBOO and LLBOO 
treated rats: The statistical estimation of calculated 
spectral HRV analysis parameters indicated differences 
between β-3 agonist treated and non-treated animals, 
Table 3.Spectral-domain HRV analysis results 
1 - Control group 2 - LLBOO group 3 - LLBOO+BRL37344
Statistic
1-2 1-3 2-3
TP [ms2] 36.09±17.83 2.68 ± 1.29 12.21 ± 11.88 0.007 0.02 0.05
VLF [ms2] 19.23±15.74 2.06 ± 1.02 9.64 ± 9.80 0.04 NS 0.05
LF [ms2] 5.40±2.54 0.11 ± 0.06 1.03 ± 1.22 0.005 0.007 NS
HF [ms2] 11.47±8.88 0.51 ± 0.38 1.55 ± 1.28 0.03 0.03 NS
LF/HF 0.70±0.63 0.26 ± 0.16 0.63 ± 0.44 NS NS 0.05
nLF [n.u.] 36.61±16.04 19.67 ± 9.59 34.77 ± 17.52 0.04 NS 0.05













Fig. 1. HRV spectrum comparision in studied groups (detailed results are given in table 3)
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2.The animals treated with β-3 agonist, BRL37344, dis-
played similar HRV results as those observed in the 
controls. We demonstrated no significant differences 
in time-domain HRV parameters compared to the con-
trol, except that rMSSD was still much lower in treated 
rats. In spectral analysis, a power decrease in LF and HF, 
together with a fall in TP, were found when compared 
to the control; although, TP and VLF achieved higher 
values in BRL37344-treated animals than in those that 
did not receive treatment. Notably, both normalized 
spectral parameters (nLF and nHF) reached almost the 
same values in control and β-3 agonist-treated rats. All 
of these findings suggest that following the administra-
tion of β-3 agonist, the global activity and functioning 
of ANS was improved; in particular, there was a mark-
edly smaller disproportion between the sympathetic 
and parasympathetic tone in this group.
3.Our results, which are in agreement with literature 
reports [18,20,24,41], suggest that β-3 agonist (BRL37344) 
seems not only to ameliorate bladder overactivity dur-
ing the storage period, but may be also considered as 
an agent abolishing the autonomic imbalance present 
in the course of LLBOO. Thus, the restoration of appro-
priate autonomic activity may contribute to relieving 
the symptoms of bladder overactivity in β-3 treated 
patients.
The results of sparse clinical reports estimating the 
functional condition of ANS appear to be ambiguous 
and conflicting. These discrepancies are due to dif-
ferences in methodological approach of the investi-
gations (some of them are based on short-term ECG 
recordings; whereas, others on 24-hourlong Holter 
ECG registrations). Moreover, the studies were con-
analysed groups. In control animals, the disproportion 
between three non-normalized spectral components was 
smaller than in other groups. We found that the percent-
age of LF differed considerably in both LLBOO populations. 
In LLBOO non-treated animals, this component amounted 
to about 4.21%, whereas in BRL37344 treated animals this 
parameter reached an almost twice higher value, 8.51%, in 
relation to the appropriate total powers. Contrary to LF% 
differences, the remaining non-normalized spectral com-
ponents (VLF, HF) achieved nearly the same percentages 
related to the appropriate total powers (%VLF – 76.62 in 
LLBOO animals and 70.41 in the tested drug treated group, 
while %HF was 19.81 and 21.09, respectively).
The distributions of the individual HRV non-normalized 
spectral components in all studied groups are given in 
figures 3-5.
dIscussIon
The main finding of our study was to demonstrate the 
autonomic nervous system disturbances in long-lasting 
experimental bladder outlet obstruction (LLBOO) model. 
We revealed that:
1.LLBOO animals were characterized by diminished 
NN range, SDNN, and rMSSD in time-domain analysis 
as compared to the control. Similarly, total power and 
non-normalized spectral HRV parameters were also 
decreased. Contrary to these findings, normalized spec-
tral parameters were lower (nLF) and higher (nHF) than 
in the controls. These findings suggest a global dimin-
ishing in ANS activity, with marked parasympathetic 
predominance, which may be at least co-responsible for 















Fig. 2. HRV normalised spectral components in the studied groups (detailed results are given in table 3)
856
Postepy Hig Med Dosw (online), 2013; tom 67: 848-858
ducted on two populations of BPH patients, which 
differed with regards to their pathophysiological con-
ditions (BPH patients with BPH accompanying met-
abolic syndrome or isolated BPH patients). The high 
sympathetic activity demonstrated in the metabolic 
syndrome may also constitute the cause of prostate 
growth. There are reports confirming such depen-
dence [9,28]. In one of our previous clinical stud-
ies, we also obtained results confirming sympathetic 
overactivity in resting conditions in BPH patients 
[37]. According to these findings, the patients should 
be treated using α-1 adrenolytic agents, reducing the 
degree of prostate hypertrophy and urethra compres-
sion by the prostatic smooth muscles [10,29]. This is 
especially important considering that α-adrenergic 
receptors were found to be present in the urinary 
bladder. The α-adrenergic receptors, in contrast to 
β-adrenergic receptors, contribute to bladder con-
traction; although, to a markedly smaller degree than 
M1 and M3 muscarinic receptors. Consequently, the 
abovementioned ideas substantiate α-adrenergic 
blockade as a potential therapeutic option. More-
over, antagonistic influence on α-adrenoreceptors 
improves bladder blood flow and protects against 
ischaemic changes [10]. Nevertheless, there is a sub-
population of BPH patients with findings of differ-
ent autonomic disturbances. Kim et al. [23] showed a 
decrease in TP and HF in short-term HRV recordings, 
without changes in the remaining non-normalized 
spectral components. Conversely, Zorba et al. [43], in 
one of the recently published works, revealed an obvi-
ous increase in all non-normalized HRV components 
(VLF, LF, and HF), although this increase was not sta-
tistically significant.
It is difficult to compare the results of experimental and 
clinical reports, not only with regards to the method-
ological differences, but also taking into account physi-
ological conditions (different rat and human resting 
heart rate, different spectral bands for basic HRV com-
ponents). Therefore, we have reservations about the 
above-cited papers; although, our results are in agree-
ment with the conclusions formulated by Kim et al. [23].
Using a similar experimental model of bladder outlet 
obstruction (although shorter, lasting only 2 weeks), 
we have also showed a total decrease in HRV power, 
together with a decline in the two standardised com-
ponents – LF and HF, in our previous study, published 
this year [13]. The value of rMSSD parameter was also 
lower in the studied group as compared to the control 
animals. The distribution of the individual HRV power 
components demonstrated the growth of VLF percent-
age (to 90%) in BOO participants, in comparison to the 
control group, which showed a lower VLF percentage 
(only 53%) [13].
Our present study has corroborated the results of our 
abovementioned studies and confirmed the obvious 
intensification of autonomic disturbances to be present 





















Fig. 3.  The distribution of non-normalized HRV spectral components in 
control group
Fig. 4.  The distribution of non-normalized HRV spectral components in 
LLBOO group
Fig. 5.  The distribution of non-normalized HRV spectral components in 
LLBOO+BRL37344 group
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in addressing this clinical entity has been confirmed 
by reports [18,20,24,41]. We showed that the adminis-
tration of β-3 agonist (BRL37344) is associated with an 
improvement in autonomic disturbances (understood 
as an increase in the total HRV power and its individ-
ual components). Although TP, LF, and HF have consis-
tently remained lower in LLBOO rats as compared to 
the control group, there was a marked and perceptible 
trend in their growth. The key finding of our study was 
revealing the lack of the essential differences in normal-
ized parameters (nLF and nHF) in animals treated with 
BRL37344 in comparison to the corresponding results 
in the controls. The activation of β-3 adrenoreceptors 
was mirrored by the growth in nLF (from 19.67 ± 9.59 in 
LLBOO non-treated group to 34.77 ± 17.52 in β-3 treated 
group) and the fall in nHF (from 80.33 ± 9.59 to 65.23 ± 
17.52, respectively). Therefore, the administration of 
β-3 agonist decreased the considerable disproportion 
between sympathetic and parasympathetic tone, result-
ing in the restoration of sympathetic increase in the 
total HRV power. It may reflect the diminished cholin-
ergic-mediated contractility of the bladder and the aug-
mented adrenergic-evoked bladder relaxation.
Moreover, there are evidences demonstrating that long-
term bladder outlet obstruction causes diminished den-
sity of the bladder β-3 adrenoreceptors and, therefore, 
results in decrease of the inhibitory bladder response 
mediated by these receptors [19]. Thus, the increase of 
the sympathetic tension after BRL37344 may contribute 
to the relatively enlarged stimulation of the still remain-
ing β-3 adrenoreceptors and bladder smooth muscles 
relaxation.
In conclusion, our study revealed that the beneficial 
effect of the studied β-3 agonists may also result from 
correcting autonomic disturbances. In order to estab-
lish the mechanism of OAB amelioration using β-3 
agonists, further research, requiring a larger number 
of studied animals and other β-3 adrenergic agents, 
is needed.
also in the experimental model of long-lasting bladder 
outlet obstruction. We postulate that the present results 
prove deep impairment of ANS in LLBOO model. Accord-
ing to literature, the sympathetic tone is expressed 
through HR, SDNN, and LF, while parasympathetic tone 
is reflected by HF [27,34]. Taking into consideration 
these guidelines, our results confirm a decrease in the 
activity of both autonomic branches in LLBOO group. 
Moreover, we strongly emphasize that the results of nor-
malized spectral components (nLF, nHF) in LLBOO group 
seem be of particular significance, because they sug-
gest considerable autonomic imbalance accompanied 
by parasympathetic predominance. It is hard to predict 
if autonomic changes revealed in our study are one of 
the possible causative OAB factors, intensifying bladder 
overactivity, or are a “compensatory” adaptive reaction 
of the bladder, enabling an improvement in urine out-
flow by higher contractility.
As a side note, it should be noted that we also showed a 
considerable decrease in VLF in LLBOO. At present, it is 
hard to interpret this finding, because both the physi-
ological and pathophysiological mechanisms respon-
sible for the origination of VLF component remain 
unclear. Despite the fact that VLF constitutes the decid-
edly largest part of the total HRV power, the significance 
of this component remains ambiguous. VLF is thought 
to reflect thermoregulatory mechanisms, fluctuations 
in renin-angiotensin-aldosterone system activity, or 
the function of peripheral chemoreceptors. Thus, VLF 
may exert not only cardiac stress, but general systemic 
stress as well [23,27]. In our experiment, this component 
achieved slightly lower percentage value in LLBOO ani-
mals (about 76%) as compared to previously mentioned 
short-term BOO subjects (90%); although, still it was the 
largest part of the total HRV power (both in LLBOO and 
control rats).
As mentioned in the introduction, β-3 agonists con-
stitute the presently studied group of agents with the 
potential use in the treatment of OAB; their effectiveness 
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